Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alignment Healthcare, Inc. (NASDAQ: ALHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Medicare Advantage-focused health insurer. Alignment files annual and quarterly reports, along with current reports on Form 8-K, that describe its financial condition, operations and key developments in its Medicare Advantage business.
Recent Form 8-K filings show that Alignment uses these reports to announce quarterly financial results and share information discussed with investors and analysts. For example, the company has filed 8-Ks to furnish press releases on second and third quarter results and to outline discussions of strategy, market position and preliminary CMS Star Ratings. These filings often reference non-GAAP measures such as adjusted gross profit and adjusted EBITDA, which are defined and reconciled to the most comparable GAAP measures in accompanying tables.
Alignment’s SEC filings also provide detail on revenue sources and expenses. Condensed consolidated statements of operations list earned premiums and other revenue, along with medical expenses, selling, general and administrative expenses, and depreciation and amortization. Balance sheet information includes medical expenses payable, long-term debt and stockholders’ equity, giving investors a structured view of the company’s capital and obligations.
Through this page, users can track ongoing 8-K disclosures related to earnings releases, guidance updates, investor presentations and other material events. Filings may also reference CMS Star Ratings, membership expectations and risk factors summarized in the company’s Form 10-K and other periodic reports. Stock Titan enhances access to these documents with AI-powered tools that help explain terminology, highlight key sections and summarize lengthy filings, allowing investors to more quickly understand how ALHC reports its performance, membership trends and risk profile.
Alignment Healthcare (ALHC) reported an insider transaction by Director Joseph S. Konowiecki. On 11/11/2025, 4,832 shares of common stock were sold at $16.49. The filing states the sale was to satisfy tax withholding from the vesting of restricted stock units and was not a discretionary trade by the reporting person.
Following the transaction, the director beneficially owns 1,081,141 shares, held directly.
Alignment Healthcare (ALHC) — insider transaction: CEO and director John E. Kao, via the JEK Trust, sold 180,000 shares of common stock on 11/10/2025 at a weighted-average price of $16.3154. The sale was made under a Rule 10b5-1 trading plan adopted on 03/12/2025.
After the transaction, Mr. Kao beneficially owns 2,526,726 shares indirectly through the JEK Trust and 2,839,942 shares directly.
Alignment Healthcare (ALHC) reported Q3 2025 results showing strong top-line growth and a return to profitability. Revenue rose to $993.7 million from $692.4 million a year ago, driven by earned premiums of $983.7 million. Medical expenses were $868.0 million and SG&A was $110.0 million, yielding operating income of $7.7 million.
Net income was $3.7 million versus a $26.4 million loss last year, with diluted EPS of $0.02. Year-to-date, revenue reached $2.94 billion and net income was $10.0 million. Cash and cash equivalents were $618.1 million as of September 30, 2025, supported by $190.3 million of net cash provided by operating activities year-to-date. Long-term debt stood at $322.7 million (carrying value) tied to 4.25% convertible senior notes due 2029. Medical expenses payable increased to $528.8 million from $289.8 million at December 31, 2024. Shares outstanding were 199,988,515 as of September 30, 2025; as of October 27, 2025, they were 200,091,742.
Alignment Healthcare, Inc. furnished a Form 8-K to announce it issued a press release with financial results for its third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information under Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated.
Alignment Healthcare (ALHC) director reports an open‑market sale. Joseph S. Konowiecki sold 25,000 shares of common stock on 10/28/2025 at a price of $18 per share (transaction code S(1)). Following the sale, he beneficially owns 1,085,973 shares, held directly.
The footnote indicates a Rule 10b5‑1 trading plan adopted on 03/05/2025 in connection with the sale. No derivative securities transactions were reported in this filing.
Alignment Healthcare (ALHC) CEO and director John E. Kao reported the sale of 180,000 shares of common stock on 10/10/2025 under a Rule 10b5-1 trading plan adopted on 03/12/2025.
The weighted-average sale price was $17.286, with individual trades ranging from $16.97 to $17.60. Following the transaction, beneficial ownership included 2,706,726 shares held indirectly by the JEK Trust and 2,839,942 shares held directly. A prior transfer on 09/25/2025 moved 1,693,626 shares from direct ownership to the JEK Trust.
Alignment Healthcare (ALHC) Chief Medical Officer Hyong (Ken) Kim reported two non-discretionary stock sales tied to restricted stock unit vesting and a pre-existing trading plan. On
Form 144 filing for proposed sale of
Alignment Healthcare, Inc. submitted a Form 144 reporting a proposed sale of 35,500 shares of common stock, with an aggregate market value of
Qatar Investment Authority and its subsidiary Q Healthcare Holding LLC filed a Schedule 13G reporting ownership of 13,246,096 shares of Alignment Healthcare, Inc. common stock, representing 6.69% of the outstanding shares. The filing states each reporting person has sole voting and sole dispositive power over those shares and that the percent was calculated using 198,031,417 shares outstanding per Alignment Healthcares July 25, 2025 disclosure. The statement includes a joint filing agreement and a certification that the stake was not acquired to influence control of the issuer.
FAQ
What is the current stock price of Alignment Healthcare (ALHC)?
What is the market cap of Alignment Healthcare (ALHC)?
